HEMLIBRA Subcutaneous Injection, General drug use-results survey - Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia A -

HEMLIBRA Subcutaneous Injection, General drug use-results survey - Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia A - - HEMLIBRA Subcutaneous Injection, General drug use-results survey - Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia A -

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048156

Enrollment

150

Registered

2022-08-01

Start date

2022-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia A

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia A for which HEMLIBRA is scheduled to be used during the enrollment period or was used in facilities where a contract for this surveillance has been concluded.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Main survey items etc. 1) Information on facilities 2) Patient demographics 3) Prior treatment history 4) Administration status of HEMLIBRA 5) Factor eight activity and factor eight inhibitor titer prior to HEMLIBRA treatment 6) Factor eight activity and factor eight inhibitor titer after the start of HEMLIBRA 7) APTT measurement or not 8) Concomitant drugs (containing prior treatment), immunosuppressive therapy 9) Combination therapy 10) Adverse events	—

Measure

Time frame

Main survey items etc. 1) Information on facilities 2) Patient demographics 3) Prior treatment history 4) Administration status of HEMLIBRA 5) Factor eight activity and factor eight inhibitor titer prior to HEMLIBRA treatment 6) Factor eight activity and factor eight inhibitor titer after the start of HEMLIBRA 7) APTT measurement or not 8) Concomitant drugs (containing prior treatment), immunosuppressive therapy 9) Combination therapy 10) Adverse events

—

Countries

Japan

Contacts

Public ContactAyako Murayama

Chugai Pharmaceutical Co. Ltd. Safety Science 2 Dept.

murayamaayk@chugai-pharm.co.jp03-3281-6611

Outcome results